MedPath

New Fox Chase Trial Tests Risk-Adapted Approach ...

Fox Chase Cancer Center's RETAIN Bladder study explores active surveillance over bladder removal for MIBC patients post-chemotherapy, using genetic mutations and clinical features to predict treatment success. Aiming to preserve quality of life, the study identifies patients who may avoid cystectomy, with ongoing research into biomarkers and treatment efficacy.


Reference News

New Fox Chase Trial Tests Risk-Adapted Approach ...

Fox Chase Cancer Center's RETAIN Bladder study explores active surveillance over bladder removal for MIBC patients post-chemotherapy, using genetic mutations and clinical features to predict treatment success. Aiming to preserve quality of life, the study identifies patients who may avoid cystectomy, with ongoing research into biomarkers and treatment efficacy.

© Copyright 2025. All Rights Reserved by MedPath